Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of BMS-708163 in Mild to Moderate Alzheimer's Disease
NCT00810147Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of avagacestat in Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Started Feb 2009; status: completed.
02
Drugs
avagacestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00810147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00810147.